Actinium Pharmaceuticals, Inc.
ATNM- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001388320
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Actinium Pharmaceuticals, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 61 | 2 | 60 | +1 |
| Shares | 5.15M | 10.3K | 5.41M | +273.9K (+5.3%) |
| Value | $8.23M | $16.5K | $7.36M | −$861.6K (−10.5%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Goldman Sachs Group Inc | 70,358 | $95.7K | 0.00% |
| Squarepoint Ops LLC | 65,730 | $89.4K | 0.00% |
| Bailard, Inc. | 57,867 | $78.7K | 0.00% |
| Am Investment Strategies LLC | 29,356 | $40.0K | 0.01% |
| Two Sigma Securities, LLC | 12,965 | $17.6K | 0.00% |
| Nine Masts Capital Ltd | 12,940 | $17.6K | 0.00% |
| HRT Financial LP | 13,010 | $17.0K | 0.00% |
| Point72 Asset Management, L.P. | 10,295 | $14.0K | 0.00% |
| Savvy Advisors, Inc. | 10,000 | $13.6K | 0.00% |
Sold out (8)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citadel Advisors LLC | 126,615 | $202.6K |
| Marshall Wace, LLP | 26,336 | $42.1K |
| AQR Capital Management LLC | 16,805 | $26.9K |
| Advisory Services Network, LLC | 2,460 | $3.94K |
| Tower Research Capital LLC (TRC) | 555 | $888 |
| Group One Trading, L.P. | 547 | $875 |
| Groupe la Francaise | 316 | $436 |
| True Wealth Design, LLC | 2 | $4 |
Not filed for Q4 2025 yet (2)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Point72 Asia (Singapore) Pte. Ltd. | 10,295 | $16.5K |
| Cubist Systematic Strategies, LLC | 1 | $2 |